A newer shingles vaccine has been linked to reduced rates of heart attacks, strokes, and heart failure in research the study team describes as a natural experiment, meaning it draws on real-world vaccination patterns rather than randomly assigning people to receive the shot. The vaccine is Shingrix. The finding comes from the same research team that reported a connection between Shingrix and lower dementia rates two years ago, and it adds to earlier signals of cardiovascular benefit from the shot.
Shingles is a painful, often serious flare-up of the chickenpox virus from childhood in older adults. Shingrix is a recombinant vaccine, which means it uses a protein piece of the virus to train the immune system rather than a weakened live form of the pathogen. In plain terms, people who received Shingrix were less likely than unvaccinated people to have a heart attack, stroke, or heart failure.
The natural experiment design is worth understanding on its own. Researchers who use this method observe what actually happened in the world rather than running a controlled trial with randomly assigned groups. That approach can surface meaningful patterns across large populations. But it also leaves a standing question: people who actively seek vaccines may already be different from those who do not, and those differences could account for some of the gap in health outcomes. An association between Shingrix receipt and lower cardiovascular risk is not the same as proof that the vaccine causes the reduction.
Two years ago the same team drew wide attention by connecting Shingrix to lower rates of dementia. That earlier finding raised the same question about what was driving the effect. This cardiovascular result follows the same pattern from the same source, pointing to benefits from Shingrix that extend beyond what the shot was originally developed to prevent.